Skip to main content

Drug Interactions between doxorubicin and momelotinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

DOXOrubicin momelotinib

Applies to: doxorubicin and momelotinib

MONITOR: Coadministration with momelotinib may increase the plasma concentrations of drugs that are substrates of the breast cancer resistance protein (BCRP) transporter. The mechanism is decreased clearance due to inhibition of BCRP-mediated intestinal and hepatobiliary efflux by momelotinib. Clinical studies have demonstrated that concomitant use of a single dose of rosuvastatin (10 mg) with multiple daily doses of momelotinib (200 mg) increased the peak plasma concentration (Cmax) and systemic exposure (AUC) by 220% and 170%, respectively.

MANAGEMENT: Caution is advised during concomitant use of momelotinib with drugs that are substrates of the BCRP transporter, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever momelotinib is added to or withdrawn from therapy. The prescribing information for the BCRP substrate should consulted for further information.

References (1)
  1. (2023) "Product Information. Ojjaara (momelotinib)." GlaxoSmithKline

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer